NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
EPINEPHRINE (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. Approved for septic shock, cardiac arrest, ventricular fibrillation and 2 more indications. First approved in 2014.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Epinephrine is an alpha-adrenergic agonist administered via intramuscular, intravenous, or subcutaneous injection used to treat life-threatening conditions including anaphylaxis, septic shock, cardiac arrest, ventricular fibrillation, and hypotension. It works by stimulating adrenergic receptors to increase heart rate, blood pressure, and cardiac output in emergency settings.
Peak
Epinephrine is in peak commercial lifecycle with moderate competitive pressure (30), indicating stable demand but potential for team consolidation as the market matures.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications (5)
Worked on EPINEPHRINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.